Escin Ib inhibits gastric emptying, at least in part, mediated by capsaicin-sensitive sensory nerves, to stimulate the synthesis and/or release of dopamine, to act through central dopamine2 receptor, which in turn causes the release of PGs.
Escin IA (Escin IA;Aescin IA) is a triterpene saponin isolated from horse chestnut, which inhibits HIV-1 protease with IC50 values of 35 μM. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of epithelial-mesenchymal transition process by down-regulating LOXL2 expression[1][2].
Escin IIB, a natural saponin compound isolated from the seeds of horse chestnut (Aesculus hippocastanum L.), exhibits biologically positive effects on acute inflammation in animal models. Escin IIB has also demonstrated strong gastroprotective properties by significantly reducing ethanol-induced gastric mucosal lesions, highlighting its potential application in the study of anti-inflammatory mechanisms and gastric mucosal defense pathways in preclinical research.
Escin IIA, a naturally derived saponin isolated from the seeds of horse chestnut (Aesculus hippocastanum L.), has been shown to exert beneficial effects in acute inflammatory conditions in animal models. Escin IIA additionally demonstrates gastroprotective effects by reducing ethanol-induced gastric mucosal lesions in rats, thereby supporting its role in the study of anti-inflammatory and gastroprotective mechanisms in preclinical research.